Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)

Next Previous
Search
Trial Profile

A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pomalidomide (Primary) ; Prednisone
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 08 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2018 Final results assessing efficacy and safety data of a prospective phase 2 study of Pomalidomide in Myelofibrosis patients with anaemia after a median follow up of 37.5 months, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology..
    • 08 Jan 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Jul 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top